Intermittent infusion of lidocaine, magnesium sulphate and ketamine in the treatment of neuropathic pain, Chronic Regional Pain Syndrome and fibromyalgia. A pilot study.

Phase 3

• Conditions: europathic Pain; Complex Regional Pain Syndrome; Fibromyalgia; Neuropathic Pain; Anaesthesiology - Pain management; Neurological - Other neurological disorders

• Registration Number: ACTRN12619000494134
• Lead Sponsor: Daniel Ellyard

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-26
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Age > 18 years
Peripheral neuropathic pain (painful peripheral polyneuropathy, post herpetic neuralgia, trigeminal neuralgia, post surgical, post traumatic) OR Complex Regional Pain Syndrome (CRPS) OR Fibromyalgia
Average pain intensity greater than or equal to 6/10 despite oral analgesic medications

Exclusion Criteria

- Pregnancy or breastfeeding
- History of seizure disorder
-Conduction abnormality on 12 lead ECG – PR >200ms, QRS >120ms, QTc >440ms
- Heart Failure – NYHA III / IV
- Chronic Liver Impairment – albumin < 30g/L OR INR >1.3
- Chronic Renal Impairment - eGFR <60ml/min/1.73m2
- Cognitive impairment deemed sufficient enough to preclude informed consent
- English language deemed insufficient to enable informed consent
- Known allergy or intolerance of proposed study medications
- Ongoing compensation/litigation claims

Study & Design

• Study Type: Interventional
• Study Design: Not specified